chr3-50365100-G-A

Variant summary

Our verdict is Benign. The variant received -11 ACMG points: 0P and 11B. BP4_StrongBP6_ModerateBP7BS1

The NM_006030.4(CACNA2D2):​c.3183C>T​(p.Gly1061Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000308 in 1,611,686 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★).

Frequency

Genomes: 𝑓 0.00024 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00032 ( 1 hom. )

Consequence

CACNA2D2
NM_006030.4 synonymous

Scores

2

Clinical Significance

Likely benign criteria provided, single submitter B:2

Conservation

PhyloP100: 1.07

Publications

0 publications found
Variant links:
Genes affected
CACNA2D2 (HGNC:1400): (calcium voltage-gated channel auxiliary subunit alpha2delta 2) Calcium channels mediate the entry of calcium ions into the cell upon membrane polarization. This gene encodes the alpha-2/delta subunit of the voltage-dependent calcium channel complex. The complex consists of the main channel-forming subunit alpha-1, and auxiliary subunits alpha-2/delta, beta, and gamma. The auxiliary subunits function in the assembly and membrane localization of the complex, and modulate calcium currents and channel activation/inactivation kinetics. The subunit encoded by this gene undergoes post-translational cleavage to yield the extracellular alpha2 peptide and a membrane-anchored delta polypeptide. This subunit is a receptor for the antiepileptic drug, gabapentin. Mutations in this gene are associated with early infantile epileptic encephalopathy. Single nucleotide polymorphisms in this gene are correlated with increased sensitivity to opioid drugs. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Mar 2014]
CACNA2D2 Gene-Disease associations (from GenCC):
  • cerebellar atrophy with seizures and variable developmental delay
    Inheritance: AR Classification: STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
  • complex neurodevelopmental disorder
    Inheritance: AR Classification: MODERATE Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -11 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.5).
BP6
Variant 3-50365100-G-A is Benign according to our data. Variant chr3-50365100-G-A is described in ClinVar as Likely_benign. ClinVar VariationId is 530569.Status of the report is criteria_provided_single_submitter, 1 stars.
BP7
Synonymous conserved (PhyloP=1.08 with no splicing effect.
BS1
Variant frequency is greater than expected in population amr. GnomAd4 allele frequency = 0.000237 (36/152128) while in subpopulation AMR AF = 0.000327 (5/15280). AF 95% confidence interval is 0.000218. There are 0 homozygotes in GnomAd4. There are 16 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CACNA2D2NM_006030.4 linkc.3183C>T p.Gly1061Gly synonymous_variant Exon 36 of 38 ENST00000424201.7 NP_006021.2 Q9NY47-2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CACNA2D2ENST00000424201.7 linkc.3183C>T p.Gly1061Gly synonymous_variant Exon 36 of 38 1 NM_006030.4 ENSP00000390329.2 Q9NY47-2
CACNA2D2ENST00000423994.6 linkc.3207C>T p.Gly1069Gly synonymous_variant Exon 37 of 39 5 ENSP00000407393.2 C9JVC9
CACNA2D2ENST00000266039.7 linkc.3183C>T p.Gly1061Gly synonymous_variant Exon 36 of 38 1 ENSP00000266039.3 Q9NY47-3
CACNA2D2ENST00000360963.7 linkc.2976C>T p.Gly992Gly synonymous_variant Exon 36 of 38 1 ENSP00000354228.3 Q9NY47-4
ENSG00000272104ENST00000606589.1 linkc.128-1197G>A intron_variant Intron 2 of 3 3 ENSP00000476225.1 U3KQU4

Frequencies

GnomAD3 genomes
AF:
0.000237
AC:
36
AN:
152128
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000327
Gnomad ASJ
AF:
0.00173
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000324
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000287
AC:
69
AN:
240508
AF XY:
0.000325
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000875
Gnomad ASJ exome
AF:
0.00133
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000452
Gnomad OTH exome
AF:
0.000675
GnomAD4 exome
AF:
0.000316
AC:
461
AN:
1459558
Hom.:
1
Cov.:
36
AF XY:
0.000333
AC XY:
242
AN XY:
726118
show subpopulations
African (AFR)
AF:
0.0000299
AC:
1
AN:
33452
American (AMR)
AF:
0.000157
AC:
7
AN:
44698
Ashkenazi Jewish (ASJ)
AF:
0.00157
AC:
41
AN:
26098
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39686
South Asian (SAS)
AF:
0.0000464
AC:
4
AN:
86240
European-Finnish (FIN)
AF:
0.0000194
AC:
1
AN:
51662
Middle Eastern (MID)
AF:
0.00295
AC:
17
AN:
5760
European-Non Finnish (NFE)
AF:
0.000333
AC:
370
AN:
1111634
Other (OTH)
AF:
0.000332
AC:
20
AN:
60328
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.470
Heterozygous variant carriers
0
26
52
79
105
131
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000237
AC:
36
AN:
152128
Hom.:
0
Cov.:
32
AF XY:
0.000215
AC XY:
16
AN XY:
74308
show subpopulations
African (AFR)
AF:
0.0000483
AC:
2
AN:
41416
American (AMR)
AF:
0.000327
AC:
5
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.00173
AC:
6
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5188
South Asian (SAS)
AF:
0.000207
AC:
1
AN:
4830
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10620
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.000324
AC:
22
AN:
68004
Other (OTH)
AF:
0.00
AC:
0
AN:
2094
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.467
Heterozygous variant carriers
0
2
4
6
8
10
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000367
Hom.:
0
Bravo
AF:
0.000291
EpiCase
AF:
0.000273
EpiControl
AF:
0.000593

ClinVar

Significance: Likely benign
Submissions summary: Benign:2
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

Developmental and epileptic encephalopathy Benign:1
Dec 30, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

CACNA2D2-related disorder Benign:1
Apr 24, 2024
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.50
CADD
Benign
12
DANN
Benign
0.96
PhyloP100
1.1
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.060
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs200429466; hg19: chr3-50402531; API